retatrutide fda approval status october 2025 Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 clinical trials, is being sold openly across the internet and prescribed by licensed physicians online and The Thriving Black Market for

A Guardian investigation found that Retatrutide UK had a score of 4.4 on the global review site, despite purporting to offer a drug that is unlicensed and illegal to sell or buy

And youre certainly not imagining it

Research market

The Future of Retatrutide in Obesity Treatment With obesity and type 2 diabetes rates continuing to rise globally, this triple-action peptide represents a potential breakthrough in pharmacological weight management

About 40% of adults in Mississippi are obese, just one percentage point behind top-ranked West Virginia, according to federal data

Critical Safety Note: Breathalyzer estimates based on typical metabolism rates will underestimate your actual BAC when on retatrutide